Evidence map›Paper›PMID 38466087›Full record

ReviewNeuro-oncology2024

Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group.

Norbert Galldiks, Timothy J Kaufmann, Philipp Vollmuth, Philipp Lohmann, Marion Smits, Michael C Veronesi, Karl-Josef Langen, Roberta Rudà, Nathalie L Albert, Elke Hattingen and 7 more

Registry-linked trialAbstract readReview
In one paragraph

Review in Neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07567196 (ResPGlioma), which is not on this map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07567196 recruitingnot on this map

ResPGlioma: Impact of PET-Guided Resection on Survival in High-Grade Gliomas - A Multicenter Prospective Study

TypeobservationalSponsorUniversita degli Studi di GenovaRan2022 to 2029Enrolled100ConditionsGlioma Glioblastoma Multiforme, Glioma, High Grade, Glioma Surgery, Positron-Emission Tomography(PET)
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Imaging in Neuro-oncology.Seminars in neurology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Norbert GalldiksDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0002-2485-1796
Timothy J KaufmannDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Philipp VollmuthDepartment of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany.
Philipp LohmannInstitute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany.ORCID 0000-0002-5360-046X
Marion SmitsDepartment of Radiology and Nuclear Medicine and Brain Tumour Center, Erasmus MC, Rotterdam, The Netherlands.ORCID 0000-0001-5563-2871
Michael C VeronesiDepartment of Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Karl-Josef LangenInstitute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany.
Roberta RudàDivision of Neuro-Oncology, Department of Neuroscience, University of Turin, Turin, Italy.
Nathalie L AlbertDepartment of Nuclear Medicine, LMU Hospital, Ludwig Maximilians-University of Munich, Munich, Germany.
Elke HattingenGoethe University, Department of Neuroradiology, University Hospital Frankfurt, Frankfurt, Germany.
Ian LawDepartment of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Markus HuttererDepartment of Neurology with Acute Geriatrics, Saint John of God Hospital, Linz, Austria.
Riccardo SoffiettiDivision of Neuro-Oncology, Department of Neuroscience, University of Turin, Turin, Italy.ORCID 0000-0002-9204-7038
Michael A VogelbaumDepartment of Neuro-Oncology and Neurosurgery, Moffit Cancer Center, Tampa, Florida, USA.
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Michael WellerDepartment of Neurology, Clinical Neuroscience Center, and University Hospital of Zurich, Zurich, Switzerland.ORCID 0000-0002-1748-174X
Joerg-Christian TonnGerman Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain tumor diagnostics have significantly evolved with the use of positron emission tomography (PET) and advanced magnetic resonance imaging (MRI) techniques. In addition to anatomical MRI, these modalities may provide valuable information for several clinical applications such as differential diagnosis, delineation of tumor extent, prognostication, differentiation between tumor relapse and treatment-related changes, and the evaluation of response to anticancer therapy. In particular, joint recommendations of the Response Assessment in Neuro-Oncology (RANO) Group, the European Association of Neuro-oncology, and major European and American Nuclear Medicine societies highlighted that the additional clinical value of radiolabeled amino acids compared to anatomical MRI alone is outstanding and that its widespread clinical use should be supported. For advanced MRI and its steadily increasing use in clinical practice, the Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition provided more recently an updated acquisition protocol for the widely used dynamic susceptibility contrast perfusion MRI. Besides amino acid PET and perfusion MRI, other PET tracers and advanced MRI techniques (e.g. MR spectroscopy) are of considerable clinical interest and are increasingly integrated into everyday clinical practice. Nevertheless, these modalities have shortcomings which should be considered in clinical routine. This comprehensive review provides an overview of potential challenges, limitations, and pitfalls associated with PET imaging and advanced MRI techniques in patients with gliomas or brain metastases. Despite these issues, PET imaging and advanced MRI techniques continue to play an indispensable role in brain tumor management. Acknowledging and mitigating these challenges through interdisciplinary collaboration, standardized protocols, and continuous innovation will further enhance the utility of these modalities in guiding optimal patient care.

Indexed as

Brain NeoplasmsMagnetic Resonance ImagingPositron-Emission TomographyHumansamino acid PETCESTdiffusion-weighted imagingMR spectroscopyperfusion-weighted imaging

Identifiers

PMID38466087
PMCPMC11226881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.